How much revenue does Biocon make?

Biocon reported 150.52 billion INR in revenue for fiscal year 2025, up 6.0% from 141.96 billion INR in fiscal year 2024. In Q2 2026 revenue was 42.63 billion INR.

What is Biocon's largest business segment?

Biosimilars, with 90.17 billion INR or 58% of segment revenue in fiscal year 2025. Next: Contract Research, Development and Manufacturing Organisation (23%) and Generics (19%).

Where does Biocon make most of its revenue?

United States of America: 46% of revenue by region in fiscal year 2025, followed by European Union (25%).

What companies are similar to Biocon?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Lupin Limited (LUPIN.NS), Glenmark Pharmaceuticals Limited (GLENMARK.NS), Alkem Laboratories Limited (ALKEM.NS), Abbott India Limited (ABBOTINDIA.NS).

Biocon Limited (BIOCON.NS) Stock

About Biocon Limited

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardi...

At a glance

Biocon reported revenue of 150.52 billion INR for fiscal year 2025, up 6.0% from fiscal year 2024, and net income of 10.13 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 42.63 billion INR, up 20.2% from a year before. Its largest business segment, Biosimilars, brought in 58% of segment revenue in fiscal year 2025; United States of America was the largest region with 46%.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.